ENO1 and central nervous system cancer: Taking advantage of deletions of ENO1 which can occur in some types of tumors including glioma, pan-ENO inhibitors were evaluated as SF2312 and also combined with pivaloyloxymethyl (POM) to form POMSF and POMHEX, a less toxic version of the inhibitor [136].